



CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica

SEATTLE, WASHINGTON USA and TOKYO, JAPAN – September 12, 2012 – CMC Biologics, a leading contract manufacturing organization known for its technical excellence in process development and cGMP manufacture, and Innomedica, a life sciences business development company specialized in Japan market, have entered into an agreement to facilitate CMC Biologics' customer base in the Japan market.

"We view this strategic agreement with Innomedica critical for us to serve our further growing customer base in the second largest healthcare market in the world," said Gustavo Mahler, Chief Operations Officer of CMC Biologics. "Establishing an in-country commercial presence provides us with the necessary structure to localized services and communications for Japanese biotechnology and pharmaceutical customers for cGMP clinical and commercial production of biopharmaceuticals."

"We believe CMC Biologics is a great match for Japanese companies looking for premium quality biologics and flexible, committed partner with cGMP facilities in Europe and the USA," said Anna Kalmi of Innomedica. "CMC has proven capability to carry out projects successfully, raising the clients' biologics development programs to the next level."

The Japanese market is the world's second largest healthcare system totaling \$115 billion in biopharmaceutical sales and comprised of global biopharmaceutical leaders including Takeda, Otsuka, Astellas, Daiichi, Sankyo, Eisai and others. With a population of 130 million people with one of the highest GDPs in the world, the country has the fastest aging population of the seven major markets, all Japanese citizens are covered by health insurance, and as a result, high quality and innovative healthcare products are highly valued.

About CMC Biologics

CMC Biologics is a leading contract development and manufacturing organization that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world, from its facilities in Europe and the USA. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. CMC Biologics is located in Copenhagen, Denmark, and Seattle, Washington. More detailed information can be found at www.cmcbiologics.com.

About Innomedica

Innomedica is a life sciences business development company specialized in Japan market. Innomedica has provided licensing, partnering and market entry services to European, Japanese and American pharmaceutical, medical technology and health product companies since 1997. The senior personnel in Innomedica's Tokyo, London and Helsinki offices are well connected and have a long track record in international strategic business development in life sciences. More detailed information can be found at www.innomedica.fi.

###

Contacts:

Stacie D. Byars, Global Marketing
CMC Biologics
Mobile: +1-206-660-2588
email: sbyars@cmcbio.com

Morten Munk
Vice President, Business Development
CMC Biologics
Mobile: +1-425-877-8583
email: MM@cmcbio.com

Anna Kalmi
Innomedica Ltd.
Mobile: +358-400-789266
e-mail: anna.kalmi@innomedica.fi